SUBSCRIBE: eNewsletter
A post-hoc analysis of Protocol T from the DRCR Retina Network, which compared anti-vascular endothelial growth factor (VEGF) compounds aflibercept, bevacizumab, and r
According to a 2018 American Eye-Q Survey conducted by the American
November is once again being recognized as Diabetic Eye Disease Awareness Month in an effort to educate the public on the effects of diabetes on vision, risk factors and treatment options.
At this year’s Retina Subspecialty Day during the American Academy of Ophthalmology (AAO), presentations as varied as
Treating diabetic retinopathy (DR) with anti-vascular endothelial growth factor (VEGF) agents is an alternative to panretinal laser, and in some studies it has been found that “
AMD risk phenotypes are characterized in a direct-to-consumer genetic database.
Dr. Rishi Singh discusses the launch of Alcon's HYPERVIT.
Dr. Singh is a paid Alcon consultant.
Josh Anderson, head of Alcon's U.S. Surgical Retina Sales & Marketing, discusses how the NGENUITY 3D Visualization System creates an immersive surgical experience.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
